Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;7(5):533-43.
doi: 10.1586/17474086.2014.953478. Epub 2014 Aug 28.

Obinutuzumab for chronic lymphocytic leukemia

Catherine Rioufol  1 , Gilles Salles
Affiliations

Obinutuzumab for chronic lymphocytic leukemia

Catherine Rioufol et al. Expert Rev Hematol. 2014 Oct.

Abstract

Chronic lymphocytic leukemia (CLL) is a frequent hematological malignancy that is incurable using standard approaches. Two anti-CD20 monoclonal antibodies (mAb), rituximab and ofatumumab, have been approved for CLL treatment. A new glycoengineered type II humanized anti-CD20 mAb, obinutuzumab (GA101), has been developed and demonstrates increased activity against B-cell malignancies by inducing direct cell death and better antibody-dependent cellular cytotoxicity. In a recent randomized Phase III study in patients with newly diagnosed CLL and coexisting conditions, obinutuzumab plus chlorambucil demonstrated significant improvement in progression-free survival and several other outcome parameters, in contrast to rituximab plus chlorambucil. Grade 3-4 infusion-related reactions and neutropenia occurred more frequently in patients who received obinutuzumab compared with those who received rituximab; however, the rate of serious infections was similar. Obinutuzumab represents a promising new option for patients with CLL and must be investigated with other chemotherapy regimens or with new targeted agents.

Keywords: anti-CD20 monoclonal antibody; antibody-dependent cellular cytotoxicity; chlorambucil; chronic lymphocytic leukemia; direct cell death; infusion-related reaction; obinutuzumab; rituximab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources